Hodgkin Lymphoma Market to Grow at a Significant CAGR Across the 7MM by 2036 | DelveInsight

DelveInsight's "Hodgkin Lymphoma - Market Insights, Epidemiology, and Market Forecast - 2036" report delivers an in-depth understanding of Hodgkin lymphoma, historical and forecasted epidemiology, and Hodgkin lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Hodgkin Lymphoma Market Report @ https://www.delveinsight.com/report-store/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Hodgkin Lymphoma Market Report
• In January 2026, An MD Anderson trial reported a 92% complete response rate in early-stage patients treated with a novel combination therapy.
• The total market size in the 7MM for Hodgkin lymphoma is expected to grow with a significant CAGR during the forecast period (2026-2036).
• In 2023, the US accounted for the maximum share of the total market in the 7MM.
• In 2024, an estimated 8,570 new cases of Hodgkin lymphoma (4,630 in males and 3,940 in females) are expected in the United States.
• In the UK, Hodgkin lymphoma incidence rates rise significantly during childhood, peaking between ages 20 and 29, with further notable rises at ages 35-39 and 75-84; the highest rates are seen in females aged 20-24 and males aged 75-79.
• Over 80% of Hodgkin lymphoma patients can be cured with current treatment approaches, with cure rates nearing 90% in younger patients and those with early-stage favorable disease.
• In October 2023, the European Commission approved ADCETRIS (brentuximab vedotin) for previously untreated CD30+ Stage III Hodgkin lymphoma in combination with AVD (doxorubicin, vinblastine, and dacarbazine).
• The Hodgkin lymphoma pipeline has strong company involvement, with key players including Merck, Bristol Myers Squibb, Takeda, Pfizer, and Genmab, among others.

Get a Free sample for the Hodgkin Lymphoma Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Hodgkin Lymphoma?
Hodgkin lymphoma is a cancer that starts in the lymphatic system, defined by the presence of Reed-Sternberg cells. It is one of two main types of lymphoma, the other being non-Hodgkin lymphoma, and is known for its high cure rates when detected and treated early. In Hodgkin lymphoma, B-lymphocytes multiply abnormally and accumulate in areas like the lymph nodes, losing their ability to fight infections, which increases vulnerability to illness. The two main types are classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. While Hodgkin lymphoma is aggressive and can spread quickly, it is also one of the most treatable cancers.

Hodgkin Lymphoma Epidemiology Segmentation in the 7MM
• Total Incident Cases of Hodgkin Lymphoma
• Stage-specific Incident Cases of Hodgkin Lymphoma
• Type-specific Incident Cases of Hodgkin Lymphoma
• Age-specific Incident Cases of Hodgkin Lymphoma
• Gender-specific Incident Cases of Hodgkin Lymphoma
• Treatable Cases of Hodgkin Lymphoma

Download the report to understand which factors are driving Hodgkin Lymphoma epidemiology trends @ https://www.delveinsight.com/report-store/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Hodgkin Lymphoma Approved Therapies
• KEYTRUDA (pembrolizumab): Merck
KEYTRUDA is a humanized monoclonal antibody and anti-PD-1 therapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes to help detect and fight tumor cells. In October 2020, the US FDA approved an expanded label for KEYTRUDA as monotherapy for adult patients with relapsed or refractory classical Hodgkin lymphoma, granted under accelerated approval based on data from the KEYNOTE-087 trial, which showed an overall response rate of 69%, including a 22% complete remission rate.

• OPDIVO (nivolumab): Bristol Myers Squibb
OPDIVO is a human IgG4 monoclonal antibody that binds to the PD-1 receptor, blocking its interaction with PD-L1 and PD-L2 and releasing PD-1 pathway-mediated inhibition of anti-tumor immune response. In May 2016, the US FDA granted accelerated approval to OPDIVO for classical Hodgkin lymphoma, having earlier received Breakthrough Therapy Designation and Orphan Drug status for relapsed or refractory disease.

• ADCETRIS (brentuximab vedotin): Pfizer & Takeda
ADCETRIS is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody linked to the microtubule-disrupting agent MMAE via a protease-cleavable linker, designed to release MMAE upon internalization into CD30-positive tumor cells. It holds marketing authorization in more than 70 countries for relapsed or refractory Hodgkin lymphoma. In November 2022, the FDA approved ADCETRIS in combination with a multidrug chemotherapy regimen for pediatric patients 2 years and older with previously untreated high-risk classical Hodgkin lymphoma, marking the first pediatric approval for brentuximab vedotin.

Hodgkin Lymphoma Pipeline Analysis
• TEVIMBRA (tislelizumab): BeiGene
TEVIMBRA is a monoclonal antibody targeting the PD-1/PD-L1 pathway, removing inhibition of the immune response. In August 2024, BeiGene reported completion of a Phase II trial (TIRHOL) in participants with relapsed or refractory classical Hodgkin lymphoma, and in March 2024 reported a separate Phase II trial evaluating tislelizumab as a first-line treatment in patients aged 60 and older, expected to complete in 2028.

• Favezelimab/pembrolizumab: Merck
This co-formulation combines favezelimab, which binds LAG3 on tumor-infiltrating lymphocytes to block its interaction with MHC class II, with pembrolizumab, and is being evaluated in a Phase III trial for relapsed or refractory classical Hodgkin lymphoma. Phase I/II results presented at ASCO 2024 showed an overall response rate of 83%, a 37% complete response rate, and a median progression-free survival of 19.4 months in anti-PD-1-naive patients.

Hodgkin Lymphoma Companies
Merck, Bristol Myers Squibb, Takeda, Seagen, Pfizer, ADC Therapeutics, Genmab, BeiGene, Tessa Therapeutics, AstraZeneca, and others.

Discover more about therapies set to grab major Hodgkin Lymphoma market share @ https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Hodgkin Lymphoma Market Outlook
Hodgkin lymphoma market growth is supported by regulatory designations, healthcare infrastructure investments, premium therapies such as immune checkpoint inhibitors, and awareness initiatives in underserved regions. Emerging economies, regenerative medicine, and strategic collaborations may further expand opportunities. Hodgkin lymphoma commonly affects adults aged 20-39 and 65+, with more than 75% achieving cure through standard treatment. ADCETRIS targets CD30, while OPDIVO and KEYTRUDA remain important for relapsed disease. TEVIMBRA is in Phase II development. Personalized PET2-guided approaches show encouraging outcomes. Across the 7MM, the US is projected to lead in 2036, followed by Germany among EU4 markets and the UK.

Scope of the Hodgkin Lymphoma Market Report
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Coverage: 7MM (US, EU4 - Germany, France, Italy, Spain - UK, and Japan)
• Hodgkin Lymphoma Companies: Merck, Bristol Myers Squibb, Takeda, Seagen, Pfizer, ADC Therapeutics, Genmab, and others
• Hodgkin Lymphoma Therapies: KEYTRUDA, OPDIVO, ADCETRIS, TEVIMBRA, Autologous CD30 CAR-T cells, GEN3017, and others
• Hodgkin Lymphoma Therapeutic Assessment: Current marketed and emerging therapies
• Hodgkin Lymphoma Market Dynamics: Market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Hodgkin Lymphoma Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement

To know more about Hodgkin Lymphoma companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/hodgkins-lymphoma-hl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Overview at a Glance
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Treatment of Hodgkin Lymphoma
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Drugs
12. Emerging Drugs
13. Hodgkin Lymphoma: The 7MM Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.